Abstract: The present invention provides a skin cosmetic containing the following components (A), (B), (C), (D), (E), and (F): (A) 0.5 to 7 mass % of a linear saturated fatty acid having 12 to 22 of carbon atom, (B) 0.01 to 5 mass % of an organic base, (C) 0.01 to 1 mass % of an inorganic base, (D) 0.6 to 7 mass % of a linear saturated alcohol having 12 to 22 of carbon atom, (E) 0.1 to 20 mass % of an oil agent, and (F) water, wherein the total amount of the components (A) and (D) is (A)+(D)=from 1 to 14 mass %, the mass ratio of the component (A) to the total amount of the components (A) and (D) [(A)+(D)] is (A)/[(A)+(D)]=from 0.1 to 0.9, the molar ratio of the component (B) to the total amount of the components (B) and (C) [(B)+(C)] is (B)/[(B)+(C)]=from 5 to 50 mol %, and the molar ratio of the total amount of the components (B) and (C) [(B)+(C)] to the component (A) is [(B)+(C)]/(A)=more than 80 mol % and 120 mol % or less.

Abstract: The present invention provides a skin cosmetic containing the following components (A), (B), (C), (D), (E), and (F): (A) 0.5 to 6 mass % of a linear saturated fatty acid having 12 to 22 of carbon atom, (B) 0.010 to 5 mass % of an organic base, (C) 0.010 to 1 mass % of an inorganic base, (D) 0.5 to 6 mass % of a linear saturated alcohol having 12 to 22 of carbon atom, (E) 0.05 to 9 mass % of a powder, and (F) water, wherein the component (D) comprises at least a linear saturated alcohol having 12 to 20 of carbon atom, and the mass ratio of the component (E) to the total amount of the components (A) and (D) [(A)+(D)] is (E)/[(A)+(D)]=from 0.01 to 5.

Abstract: Compositions and methods are disclosed for targeted delivery of a benefit agent to areas of a human integument having melanin deposits. The compositions comprise a pyridinium compound having affinity for melanin. The compounds may be bound to a benefit agent, such as a pigment and may be topically applied to a human integument.

Abstract: Cosmetic composition comprising a combination of surfactants of carboxylate, acylisethionate and alkyl(poly)glycoside type The invention relates to a cosmetic composition comprising: one or more anionic surfactants of carboxylate type, chosen from the compounds of formule (I), R—(OCH2CH2)nW—(CHY1)p-COOX (I), in a content of greater than or equal to 3% by weight relative to the total weight of the composition, one or more anionic surfactants of (C8-C22) acylisethionate type, and -one or more nonionic surfactants of alkyl(poly)glycoside type. This composition is intended for the cosmetic treatment of keratin materials, and in particular for washing the hair. It has excellent foaming power.

Abstract: The invention relates to the use of a steroid-3-carboxylic acid ester, a steroid-4 carboxylic acid ester or a steroid-17 carboxylic acid ester of a steroid, selected from the group of androstanones, androst-4-ene-diones, androst-5-ene-diones, dehydroepiandrosterones, androstenetriones or testosterones, with an acyl group of the carboxylic acid ester where R is selected, from alkyl with at least two carbon atoms or cycloalkyl, or with the use of a compound containing these steroid carboxylic acid esters for local topical application for cosmetic or dermatological purposes. Moreover, this invention also relates to steroid carboxylic acid esters and their compounds used for local topical application.

Abstract: Surface treating and/or modifying compositions, for example cosmetic or pharmaceutical or plant protective compositions or domestic care compositions comprise a guar protein extract, or derivative thereof, such guar protein extract comprising at least 65% by weight of proteins and are particularly suitable as surface treating and/or modifying agents, wherein these surfaces are, for example, the skin, hairs, domestic care and textile surfaces and plant leaf surfaces.

Abstract: Embodiments of the invention are generally directed to compositions comprising lightening agents, nicotinamide and 3,3?-thiodipropanoic acid, in a cosmetically acceptable vehicle, articles of manufacture, and methods of use thereof. The compositions and methods of described herein are effective to lighten an area of skin in need of lightening, such as but not limited to, a subject having overall dark complexion, pigmented skin discoloration, freckles, age spots, liver spots, sun damage, tans, pigmented acne marks, scars, pigmented birthmarks, hyperpigmentation, post-inflammatory hyperpigmentation, post-injury hyperpigmentation, melasma, cholasma, after-burn scar, nail stain, yellowing of skin, dark circles under eyes, and the like. The composition may include additional ingredients accordingly for a colored cosmetic, moisturizer, cleanser, toner, and the like.

Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.

Abstract: The present invention relates to care agents comprising ethylene copolymers and to the use of the care agents or of the ethylene copolymers for improving the wet combability of hair and for achieving a waxy, groomed, soft feel to the hair.

Abstract: Compositions are disclosed that impart one or more durable hair styling benefits. The durable styling compositions comprise at least a first compound having anhydride, diacid, diester, or half-acid/half-ester functionality, and a second compound having at least one amine moiety or hydroxyl functional group. In one embodiment the durable styling composition takes the form of a leave-in product. The durable styling compositions are heat-activated, which may be accomplished through the use of a heated styling tool like a flat-iron, curling iron, and/or hair dryer. The benefits include shine, conditioning, softness, defrizzing, and improved hair alignment, and endure for up to 5 wash cycles or more without having to reapply the durable styling composition nor heat.

Abstract: A cosmetic composition for treating hair, nails and skin, including the lips, is provided, which composition comprises a UV activated self-repair film forming material, for example, a polymer, such as a polyurethane polymer, containing a polysaccharide substituted with a UV active oxetane, or a metallo-supramolecular film-former capable of reforming polymeric like chains via metal ligand complexation.

Abstract: The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable aqueous medium, at least one cationic surfactant, at least one oxyethylenated sorbitan ester and at least one non-silicone solid fatty substance, in an oxyethylenated sorbitan ester/fatty substance weight ratio ranging from 0.2 to 50. The cosmetic compositions as disclosed herein have an improved conditioning effect, for instance on hair sheen.

Abstract: The present invention is a composition in form of an emulsion, comprising at least one fatty phase, and at least one aqueous phase, and: a) at least one first surfactant chosen from C8-C22 alkyl dimethicone copolyols; b) at least one second surfactant chosen from dimethicone copolyols, which is different from the first surfactant a); c) at least one third surfactant which is different from the first or the second surfactant a) or b), having a HLB value of greater than or equal to 8; and d) at least one hydrophilic pigment.

Abstract: A composition for providing a film on keratin fibres comprises: a film-forming aminosilicone polymer; a silicone resin which is a MQ resin; a thickening system comprising a deposition enhancer and a thickening polymer; and a solvent. Also, associated methods, kits and uses are provided.

Abstract: A composition for providing a film on keratin fibres comprises: an aminosilicone polymer; a silicone resin which is a MQ resin; a thickening system comprising a thickening polymer; and a solvent. The composition has a viscosity of from 30 mPa·s to 1000 mPa·s, wherein the viscosity is measured at 23° C. The composition has a tangent delta of less than 2 at an angular frequency of 1 Hz at 23° C. and at 1% strain. Also, associated methods, kits and uses are provided.

Abstract: A method for providing a film comprising pigment on keratin fibres comprises: (a) applying a composition to hair, wherein the composition comprises: an aminosilicone polymer, wherein the aminosilicone polymer comprises amino sidechains, and wherein the aminosilicone polymer has a weight average molecular weight of from 10,000 Dalton to 60,000 Dalton; a silicone resin which is a MQ resin; a thickening system comprising a thickening polymer; one or more pigments or one or more coloured materials; a solvent; and subsequently (b) applying a coating formulation onto the hair, wherein the coating formulation comprises a silicone resin and a volatile solvent; wherein the keratin fibres are not rinsed between steps (a) and (b). Also associated kits and uses thereof.

Abstract: A composition for providing a film on keratin fibres, the composition comprising: an aminosilicone polymer; a silicone resin; an ether of a water-soluble polyhydric alcohol; a thickening system comprising a deposition enhancer and a thickening polymer; one or more coloured materials or one or more pigments; water; and a volatile alcohol. Also, associated methods, kits and uses.

Abstract: A composition for providing a film on keratin fibres, the composition comprising: a film-forming aminosilicone polymer; a silicone resin; an ether of a water-soluble polyhydric alcohol; a thickening system comprising a deposition enhancer and a thickening polymer; one or more coloured materials or one or more pigments; water; 2-phenoxyethanol and/or phenylmethanol; wherein the composition is substantially free of esters of parahydroxybenzoic acid; and wherein the composition is substantially free of isothiazolinone compounds. Also, associated methods, kits and uses.

Abstract: A composition for providing a film on keratin fibres, the composition comprising an aminosilicone polymer; a silicone resin which is a MQ resin; a thickening system comprising a thickening polymer; water; one or more pigments or one or more coloured materials; wherein when drying the composition spread with an average wet thickness of 37 micron the fluidity factor is measured to form a drying curve of fluidity factor over time, wherein the fluidity factor is within the range of 10 Hz to 0.001 Hz within the first 15 minutes of drying and the fluidity factor reduces by at least a factor of 100 within the first 15 minutes of drying; wherein the drying curve of fluidity factor over time is measured according to the fluidity factor measurement method and at 23° C. and ambient conditions. Also associated methods, kits and uses.

Abstract: Methods of using extracts of Antidesma bunius to impart benefits to skin and/or improve skin conditions resulting from aging or damaged skin.

Abstract: A cosmetic composition and its use as an antioxidant and bleaching agent is described. In particular, said composition comprises different active ingredients, among them a botanical extract, and cosmetically acceptable excipients. The active compounds are selected from ferulic acid, olive leaves extract, maslinic acid, Octadecyl Di-t-butyl-4-hydroxyhydrocinnamate and BHT.

Abstract: This invention discloses various cosmetics and topical formulations comprising cannabigerol, a non-psychoactive cannabinoid. The formulation may be an anti-aging cream for day or night application, a hand and nail cream, an eye cream, an acne treatment cream or tonic, an anti-diaper rash cream, a shampoo, a conditioner, a body wash, a face wash, deodorant spray, or a lip balm formulation. These topical and cosmetic formulations have speedy wound healing, skin firming, anti-bacterial, anti-dandruff, skin soothing, and UV ray protection properties.

Abstract: The present invention provides for an oral serum made from natural ingredients that advantageously reduces oral bacteria. Further, toothpaste and oral rinse compositions are provided. A method for reducing oral bacteria using the oral serum of the present invention is additionally described herein.

Abstract: A capsule includes a compressible reservoir and a gas generating unit disposed in a housing. A threshold valve seals an opening in the housing, through which contents of the reservoir may exit the capsule. Gas generated by the gas generating unit increases pressure in the capsule, thereby compressing the reservoir. When a pressure acting on the threshold valve reaches a threshold pressure, the threshold valve opens, releasing contents of the reservoir.

Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.

Abstract: The present invention relates to a process for manufacturing an ophthalmic formulation of a carbonic anhydrase inhibitor, hydroxyl ethyl cellulose (HEC), and a beta-adrenergic antagonist for use in the treatment of ocular hypertension and glaucoma wherein the ophthalmic pharmaceutical formulation is devoid of benzalkonium chloride or any other preservatives. The present process for manufacturing is simpler, cost effective process to prepare the pharmaceutical ophthalmic formulation in a single tank, without the use of additional tanks that can be sterile filtered.

Abstract: Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.

Abstract: A method is disclosed for making a pharmaceutical composition for pulmonary administration comprising a pharmaceutically active protein or nucleic acid particle, the method comprising a step in which the inhalable pharmaceutically active protein or nucleic acid particle is acoustically blended in a resonant acoustic blender. The invention also relates to compositions for inhalation prepared by the method.

Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

Abstract: The present invention provides a process for preparing a water dispersion containing a high concentration of nano/submicron, hydrophobic, functional compounds. The process is carried out by using a complex stabilizer having an HLB value of about 10 to about 17, comprising lecithin and at least one non-phospholipid selected from polysorbate, sucrose ester, and polyglycerol fatty acid ester; selecting a specific weight ratio of the hydrophobic functional compounds and the stabilizer; and using homogenization technique, media milling technique, and/or centrifugal technique. The water dispersion containing a high concentration of nano/submicron, hydrophobic, functional compound produced by the process of the invention has stable dispersibility and improved bioavailability, and can be applied to the fields of foods and pharmaceuticals.

Abstract: The present invention is directed to emulsions with a plurality of droplets dispersed in a continuous liquid medium. These droplets can contain at least a first droplet liquid and a second droplet liquid and can have an ensemble-average maximal spatial dimension that is less than 1 micrometer. The invention includes preparation, uses and compositions containing emulsions. Solute materials can also be dissolved in the droplet liquids.

Abstract: The present invention relates to a liposomal pharmaceutical preparation containing a multivalent ionic drug, a process for the preparation of the liposomal pharmaceutical preparation, and a use thereof in the treatment of diseases, in which the liposome has a size of about 30-80 nm, and the phospholipid bilayer has a phospholipid with a Tm higher than body temperature, so that the phase transition temperature of the liposome is higher than the body temperature.

Abstract: A reconstituted high density lipoprotein composition including negatively charged phospholipids enhances cholesterol clearance, reduces inflammation and other anti-atherosclerotic actions.

Abstract: The present invention relates to a delayed release pharmaceutical formulation for delivering an active agent to the intestine, a method of preparing such formulation and the use of such formulation in the treatment of gastrointestinal disorders.

Abstract: Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.

Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

Abstract: Disclosed are methods for hydration of ST-246 particles comprising exposing said particles to moisture by conveying volumes of air containing moisture.

Abstract: A method of converting a poorly water soluble crystalline compound to an amorphous compound and a method of increasing the solubility of a poorly water soluble crystalline compound in biorelevant fluid at pH 6.5 is disclosed. The method includes dissolving the compound and a polymer in a solvent to form a solution, the polymer being present in the solution in an amount such that after electrospraying the solution the compound is in an amorphous form, electrospraying the solution using an electrospray system, the electrospraying forming nanoparticles, collecting the nanoparticles on a substrate, and removing the nanoparticles in the form of a powder.

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.

Abstract: The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. Arsenic treatment has shown great promise in the treatment of several cancers but requires daily intravenous (IV) administration. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. As a result, the formulation facilitates a systemic bioavailability comparable to that of intravenous (IV) administration of arsenic trioxide currently practiced.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.

Abstract: A liquid composition which comprises an organic liquid diluent and a hydroxyalkyl methylcellulose which has a certain distribution of substituted hydroxyalkoxyl groups and unsubstituted hydroxyalkoxyl groups is stable over an extended time period. In the hydroxyalkyl methylcellulose hydroxyalkoxyl groups are classified into a fraction (A) and a fraction (B), wherein fraction (A) represents the sum of all molar fractions of substituted hydroxyalkoxyl groups having hydroxyl groups substituted further with methoxyl groups and fraction (B) represents the sum of all molar fractions of unsubstituted hydroxyalkoxyl groups having hydroxyl groups not substituted further with methoxyl groups and wherein the ratio fraction (A)/fraction (B) is at least 0.30. The liquid composition is useful for preparing a solid dispersion comprising at least one active ingredient in at least one hydroxypropyl methylcellulose by spray-drying.

Abstract: Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular Crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.

Abstract: This invention relates to a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol lipid microsphere preparation having 2,2?,6,6?-tetraisopropyl-4,4?-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water.

Abstract: The invention relates to capsules of core/shell type, the core comprising an active agent; the shell comprising one or more concentric and alternating layers of a first photosensitive anionic amino polymer and of a second cationic polymer. The invention also relates to a cosmetic or pharmaceutical composition comprising such capsules. The invention also relates to a non-therapeutic cosmetic process for treating keratin materials, comprising the application to the keratin materials of a cosmetic composition comprising the said capsules, followed by exposure of the deposit formed on the keratin materials to natural light or to artificial light with a wavelength of between 360 and 600 nm.

Abstract: There is provided a supercritical fluid-based process for preparing a solid polymer matrix containing a core material, wherein the process includes the step of mixing the polymer, core material and supercritical fluid in a mixing vessel, followed at least one cycle of, without recovering the solid polymer matrix, (i) converting the supercritical fluid in the mixing vessel to a sub-critical state, and then (ii) returning the fluid to the supercritical state, provided that the core material does not comprise any of gonadotropin releasing hormone (GnRH), a GnRH agonist and a GnRH antagonist.

Abstract: Solid dosage forms containing nanoparticles are prepared where sugar esters serve as nanoparticle stabilizers that prevent agglomeration of nanoparticles during preparation of the solid dosage form and allow for restoration of the original nanoparticle size of the nanoparticles upon redispersion of the solid dosage form in aqueous media.

Abstract: Methods and devices for making particles at small volumes.

Abstract: The present invention relates to a transdermal patch comprising a pharmaceutical formulation, the formulation comprising ropivacaine or an opioid, a pharmaceutically-acceptable adhesive and optionally one or more excipients selected from the group consisting of carrier oils, penetration enhancers and hydrophilic materials. The present invention also relates to methods of preparation of such a pharmaceutical formulation, as well as the use of such a transdermal patch in the treatment of pain (e.g. nociceptive and/or neuropathic pain).